World Pharma News Digest

FDA Accepts sNDA for Expanded Use of Angiomax®
The Medicines Company (NASDAQ: MDCO) announced that the U.S. Food and
Drug Administration (FDA) has accepted the Company's supplemental new
drug application (sNDA) for a modified dosing regimen of Angiomax®
(bivalirudin) for the treatment of acute coronary syndromes (ACS),
specifically in patients with unstable angina or non-segment elevation
myocardial infarction (NSTEMI).
Read more...
http://www.worldpharmanews.com/content/view/127/1/

Protherics licenses its Covaccine HT adjuvant to Nobilon for influenza
vaccine indications
Protherics PLC, the international biopharmaceutical company focused on
critical care and cancer, and Nobilon International B.V., part of
Organon, the human health care business unit of Akzo Nobel, today
announced that Nobilon has licensed Protherics' CoVaccine HT™ adjuvant
for use in pandemic influenza vaccines and seasonal influenza vaccines
in elderly people.
Read more...
http://www.worldpharmanews.com/content/view/126/1/

Launch of a broad public debate on the future of pharmaceuticals for
human use in Europe
The Commission launches a public consultation on the future of
pharmaceuticals for human use in Europe. The pharmaceutical sector has
been and remains a key strategic sector in Europe. The future of this
sector is a crucial matter for the EU.
Read more...
http://www.worldpharmanews.com/content/view/125/1/

Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus™ Therapeutics
announced the companies have signed a definitive agreement under which
Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics,
developer of a new therapeutic class of biologics called Adnectins™.
Read more...
http://www.worldpharmanews.com/content/view/124/1/

Scientists discover how brain regulates fat metabolism
Scientists have discovered the brain region which controls whether
excess energy should be stored as fat or burned in our muscles. The
researchers hope that their findings will lead to the development of
new treatments for obesity. The work, which was partly funded by the
EU, is published in the Journal of Clinical Investigation.
Read more...
http://www.worldpharmanews.com/content/view/123/1/

Protherics signs ReGel™ licensing agreement with Myungmoon Pharm
Protherics PLC, the international biopharmaceutical company focused on
critical care and cancer, today announces that it has signed a
licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean
pharmaceutical company, granting it the rights to develop anti-
inflammatory products using Protherics' local, sustained release drug
delivery system ReGel™.
Read more...
http://www.worldpharmanews.com/content/view/122/1/

Lundbeck in-licenses Circadin®, a drug approved for the treatment of
primary insomnia
H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. announced that
Lundbeck has in-licensed the exclusive rights for Circadin® for the
treatment of primary insomnia for the majority of markets in Europe
including the five major markets. Furthermore, Lundbeck holds the
exclusive option to evaluate commercialization in markets outside of
Europe.
Read more...
http://www.worldpharmanews.com/content/view/121/1/

First in a New Oral Class of HIV Medicines in 10 Years
Pfizer Inc. announced today that the European Commission (EC) has
approved Celsentri® (maraviroc). Treatment-experienced HIV patients in
the EU can soon benefit from the first CCR5 antagonist and only oral
entry inhibitor. Maraviroc, in combination with other antiretroviral
medicinal products, is indicated for treatment-experienced adult
patients infected with only CCR5-tropic HIV-1 virus detectable.
Read more...
http://www.worldpharmanews.com/content/view/120/1/

Best regards,
Ruslan David, MD
eHealthNews.EU Portal & World Pharma News
Administrator/Editor
http://www.ehealthnews.eu
http://www.worldpharmanews.com

.

Relevant Pages

  • World Pharma News Digest
    ... Drug Administration has accepted the Company's supplemental new ... Protherics licenses its Covaccine HT adjuvant to Nobilon for influenza ... pharmaceuticals for human use in Europe. ...
    (sci.med.pharmacy)
  • Re: Judaism or Calvinism? (was: Re: Jewish unity re childrens health bill)
    ... pharmaceuticals in Canada, and in much of Europe. ... but wanted to expand on my answer to Eliyahu. ... a "good" drug. ...
    (soc.culture.jewish.moderated)
  • Oral Treatment
    ... Copyright 2005 Drug Week via NewsRx.com & NewsRx.net ... IND submitted to U.S. FDA for oral treatment of relapsing multiple sclerosis ... laquinimod in relapsing forms of MS, is planned to start in 2006. ... development of pharmaceuticals in the area of autoimmune/inflammatory ...
    (alt.support.mult-sclerosis)
  • California discovers Big Pharmas medical ethics
    ... California Accuses Drug Companies of Fraud ... Abbott Laboratories and Wyeth Pharmaceuticals, ... prices Medi-Cal and other state Medicaid operations pay were ...
    (sci.med.diseases.lyme)
  • Re: Travel writer Rick Steves comments on drug war
    ... Europe has a drug problem, ... I got a close look at the alternative to a war on drugs. ... shocks some American sensibilities with its underage drinking, ...
    (rec.music.gdead)